Wiley Matthew T.

Wiley Matthew T. is listed in filings as Chief Commercial Officer at Definium Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 22, 2026, including sale activity. Recent filings connect the profile to Definium Therapeutics, Inc. (DFTX) and BioXcel Therapeutics, Inc. (BTAI). The current snapshot covers public activity from Jun 18, 2024 to Jun 22, 2026. Reported amounts are shown as $2.2M to $149. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.